Drug intelligence / Profile preview

OFD + atazanavir

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

OFD + atazanavir is a combination drug consisting of "OFD" and "atazanavir." Atazanavir is an antiretroviral medication in the class of protease inhibitors, used in combination with other agents to treat human immunodeficiency virus (HIV) infection. It works by inhibiting the HIV-1 protease enzyme, thereby preventing viral replication and reducing viral load in patients[2][3][4]. Atazanavir is often administered with pharmacokinetic boosters such as ritonavir or cobicistat to enhance its effectiveness[2][3][7]. The identity, mechanism, and role of "OFD" are not established based on available sources; therefore, this entry specifically describes the known component (atazanavir) within the context of a combination product.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on OFD + atazanavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OFD + atazanavir.

Explore the full profile